Related Experiment Video

Updated: Jun 23, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous

Masahisa Jinushi1, Marimo Sato, Akira Kanamoto

  • 1Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

The Journal of Experimental Medicine
|May 13, 2009
PubMed

Insights

Blocking milk fat globule epidermal growth factor-8 (MFG-E8) enhances cancer therapies by promoting tumor cell death and boosting anti-tumor immunity. This approach combines with chemotherapy, targeted therapy, and radiation for improved outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Carcinogenesis involves complex interactions between tumor and host cells.
  • Current cancer treatments often target tumor and host compartments independently.
  • Milk fat globule epidermal growth factor-8 (MFG-E8) promotes tumor progression and immune suppression within the tumor microenvironment.

Purpose of the Study:

  • To investigate the potential of systemic MFG-E8 blockade in combination with existing cancer therapies.
  • To elucidate the mechanisms by which MFG-E8 blockade enhances anti-tumor responses.

Main Methods:

  • Utilized established mouse tumor models.
  • Administered systemic MFG-E8 blockade in conjunction with cytotoxic chemotherapy, molecularly targeted therapy, and radiation therapy.
  • Assessed tumor destruction, apoptosis, dendritic cell cross-presentation, and T cell responses (effector T cells and FoxP3(+) T regulatory cells).

Main Results:

  • Systemic MFG-E8 blockade synergized with chemotherapy, targeted therapy, and radiation to induce significant destruction of established mouse tumors.
  • Combination treatments resulted in extensive tumor cell apoptosis.
  • Apoptotic tumor cells facilitated efficient dendritic cell cross-presentation, leading to potent anti-tumor effector T cell responses.
  • MFG-E8 blockade inhibited FoxP3(+) T regulatory cells, contributing to long-term protective immunity.

Conclusions:

  • Systemic MFG-E8 blockade is a promising strategy to enhance the efficacy of conventional cancer treatments.
  • The combination therapy leverages both cell-autonomous (apoptosis) and immune-mediated (T cell activation) mechanisms.
  • Targeting MFG-E8 offers a novel approach to overcome treatment resistance and improve long-term anti-tumor immunity.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...